Non‐small cell lung cancer in China

Cancer Communications, Journal Year: 2022, Volume and Issue: 42(10), P. 937 - 970

Published: Sept. 8, 2022

In China, lung cancer is a primary type with high incidence and mortality. Risk factors for include tobacco use, family history, radiation exposure, the presence of chronic diseases. Most early-stage non-small cell (NSCLC) patients miss optimal timing treatment due to lack clinical presentations. Population-based nationwide screening programs are significant help in increasing early detection survival rates NSCLC China. The understanding molecular carcinogenesis identification oncogenic drivers dramatically facilitate development targeted therapy NSCLC, thus prolonging positive drivers. exploration immune escape mechanisms, programmed death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitor monotherapy PD-1/PD-L1 plus chemotherapy have become standard care advanced Chinese Society Clinical Oncology's guidelines maintenance immunotherapy recommended locally after chemoradiotherapy. Adjuvant neoadjuvant chemoimmunotherapy will be approved resectable NSCLC. this review, we summarized recent advances China terms epidemiology, biology, pathology, pathogenesis, screening, diagnosis, therapy, immunotherapy.

Language: Английский

---

From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 154959 - 154959

Published: Nov. 19, 2023

Language: Английский

---

Promotion of ROS-mediated apoptosis, G2/M arrest, and autophagy by naringenin in non-small cell lung cancer

International Journal of Biological Sciences, Journal Year: 2024, Volume and Issue: 20(3), P. 1093 - 1109

Published: Jan. 1, 2024

Background: As lung cancer is the leading cause of death worldwide, development new medicines a crucial endeavor.Naringenin, flavanone derivative, possesses anti-cancer and anti-inflammatory properties has been reported to have cytotoxic effects on various cells.The current study investigated underlying molecular mechanism by which naringenin induces cell in cancer.Methods: The expression apoptosis, cycle arrest, autophagy markers H1299 A459 cells was evaluated using terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL), Western blot, Annexin V/PI stain, PI acridine orange staining, transmission electron microscopy (TEM).Using fluorescence microscopy, DALGreen used observe degradation p62, GFP-LC3 plasmid evaluate puncta formation, pcDNA3-GFP-LC3-RFP-LC3ΔG flux.Furthermore, effect subcutaneous xenograft model.Results: Naringenin treatment (H1299 A459) reduced viability induced arrest.Pretreatment with ROS scavengers (N-acetylcysteine or catalase) suppressed naringenin-induced cleavage apoptotic protein restored cyclin-dependent kinase activity.Naringenin also triggered mediating generation, thereby activating AMP-activated (AMPK) signaling.ROS inhibition not only inhibited autophagic formation but decreased ratio microtubule-associated proteins 1A/1B light chain 3 II (LC3II)/LC3I activity AMPK signaling pathway.Furthermore, tumor growth promoted apoptosis mouse model. Conclusion:This demonstrated potent cells, providing valuable insights for developing small-molecule drugs that can induce death.

Language: Английский

---

Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(6), P. 912 - 927

Published: Jan. 25, 2024

J o u r n a l P e -p f patients in the iruplinalkib group (median PFS, 27.7 months [95% CI, crizotinib group; HR, 0.34 [98.02% 0.23-0.52];p<0.0001).The ORR assessed by IRC was 93.0% (95% 87.5-96.6) and 89.3% 83.1-93.7) group.The intracranial 90.9% (10/11, 95% 58.7-99.8) 60.0% (9/15, 32.3-83.7) for with measurable baseline CNS metastases.Incidence of grade 3 or 4 treatment-related adverse events 51.7% 49.7% group.Interpretation: Iruplinalkib demonstrated significantly improved PFS antitumor activity versus crizotinib.Iruplinalkib may be new treatment option advanced ALK positive TKI-naïve NSCLC.

Language: Английский

---

Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, large-sample informatics study

International Journal of Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: April 23, 2024

Neoadjuvant and adjuvant immunotherapies for cancer have evolved through a series of remarkable critical research advances; however, addressing their similarities differences is imperative in clinical practice. Therefore, this study aimed to examine from the perspective informatics analysis.

Language: Английский

---

Emerging role of exosomes in cancer therapy: progress and challenges

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 13, 2025

This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple types. As small extracellular vesicles, exosomes exhibit high biocompatibility low immunogenicity, making them ideal vehicles capable of efficiently targeting cells, minimizing off-target damage side effects. aims to explore the potential with a focus on applications chemotherapy, gene immunomodulation. Additionally, challenges related production standardization are analyzed, highlighting importance addressing these issues clinical application. In conclusion, systems offer promising future therapies. Further research should aim enhance efficiency facilitate translation, paving way innovative treatment strategies.

Language: Английский

---

Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape

Current Oncology, Journal Year: 2023, Volume and Issue: 30(6), P. 5906 - 5931

Published: June 19, 2023

The present review aimed to establish an understanding of the pathophysiology leptomeningeal disease as it relates late-stage development among different cancer types. For our purposes, focused metastatic malignancies include breast cancer, lung melanoma, primary central nervous system tumors, and hematologic cancers (lymphoma, leukemia, multiple myeloma). Of note, discussion was limited cancer-specific metastases secondary aforementioned cancers. LMD mechanisms non-cancerous pathologies, such infection or inflammation layer, were excluded from scope review. Furthermore, we intended characterize general disease, including specific anatomical infiltration process/area, CSF dissemination, manifesting clinical symptoms in patients afflicted with detection mechanisms, imaging modalities, treatment therapies (both preclinical clinical). these parameters, across shares several features. Pathophysiology regarding CNS involvement within mentioned subtypes is similar nature progression disease. Consequently, regardless type, employs same techniques. Cerebrospinal fluid analysis combination varied (CT, MRI, PET-CT) has been noted current literature gold standard diagnosis metastasis. Treatment options for are both currently development, given rarity cases. Our details differences they pertain through lens effort highlight state targeted therapy, potential shortcomings treatment, direction treatments future. As there a lack comprehensive reviews that seek metastasis various solid altogether, authors not only overlapping but also distinct patterning means uniquely treat each type. scarcity cases poses barrier more robust evaluations this pathology. However, have improved over time, so incidence LMD. increase diagnosed represents small fraction LMD-afflicted patients. More often than not, determined upon autopsy. motivation behind stems increased capacity study spite poor patient prognosis. In vitro cells allowed researchers approach at level markers. We ultimately hope facilitate translation research discourse.

Language: Английский

---

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 167, P. 115514 - 115514

Published: Sept. 15, 2023

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and constitutively expressed on surface of immune cells. As a receptor checkpoint, PD-1 can bind to programmed ligand-1/programmed ligand-2 (PD-L1/PD-L2) in tumor cells, leading evasion. Anti-PD-1 anti-PD-L1 are important components therapy. as an intrinsic variant (iPD-1) cancer cells where it plays roles malignant progression proposed recent studies. However, iPD-1 has received much less attention compared although there unmet medical need for fully elucidating mechanisms actions achieve best response immunotherapy. suppresses tumorigenesis non-small lung (NSCLC) colon cancer, whereas promotes melanoma, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), thyroid (TC), glioblastoma (GBM), triple-negative breast (TNBC). In this review, we focus role development its molecular mechanisms. We deeply discuss nivolumab-based combined therapy common may explain different therapeutic effects anti-PD-1 treatment provide critical information use anti-tumor approaches.

Language: Английский

---

Exploring the Anticancer Potential of Traditional Thai Medicinal Plants: A Focus on Dracaena loureiri and Its Effects on Non-Small-Cell Lung Cancer

Plants, Journal Year: 2024, Volume and Issue: 13(2), P. 290 - 290

Published: Jan. 18, 2024

Non-small-cell lung cancer (NSCLC) is renowned for its aggressive and highly metastatic nature. In recent years, there has been a surge in interest regarding the therapeutic potential of traditional medicinal plants. Dracaena loureirin (D. loureirin), Ficus racemosa Linn. (F. racemosa), Harrisonia perforata (Blanco) Merr. (H. perforata) are prominent herbs Thailand, recognized their diverse biological activities, including antipyretic anti-inflammatory effects. However, prospective anti-cancer properties against NSCLC remain largely unexplored. This study aimed to evaluate attributes ethanolic extracts obtained from D. loureiri (DLEE), F. (FREE), H. (HPEE) A549 adenocarcinoma cell lines. Sulforhodamine B (SRB) assay results revealed that only DLEE exhibited cytotoxic effects on cells, whereas FREE HPEE showed no such cytotoxicity. To elucidate mechanisms DLEE, cycle apoptosis assays were performed. The findings demonstrated inhibited proliferation induced arrest at G0/G1 phase cells through downregulation key regulator proteins, cyclin D1, CDK-2, CDK-4. Furthermore, treatment facilitated by suppressing anti-apoptotic proteins (Bcl-2, Bcl-xl, survivin) enhancing apoptotic (cleaved-caspase-3 cleaved-PARP-1). summary, our provides novel insights into significant cells. work represents first report suggesting capability impede growth induction apoptosis.

Language: Английский

---

Bioinformatics and experimental approach identify lipocalin 2 as a diagnostic and prognostic indicator for lung adenocarcinoma

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 272, P. 132797 - 132797

Published: June 1, 2024

lipocalin 2 (LCN2) is a secreted glycoprotein that plays key roles in tumorigenesis and progression. Interestingly, LCN2 appears to have contradictory function developing lung adenocarcinoma (LUAD). Thus, we intend explore the role of LUAD through bioinformatics experimental validation. expression was investigated TCGA, TIMER HPA databases. The relationship between prognosis by KM plotter, TCGA GEO GO, KEGG protein-protein interactions network analysis were conducted investigate potential mechanism LCN2. relevance cancer-immune infiltrates Quantitative reverse transcription PCR, western blot enzyme-linked immunosorbent assay performed identify level cells serum samples. CCK-8, wound healing transwell used confirm effect on cell proliferation, migration invasion LUAD. receiver operating characteristic curve utilized assess diagnostic efficiency further. significantly upregulated (P < 0.05), correlated with clinical stage, tumor size, lymph node metastasis distant 0.05). There high correlation worse Functional suggested associated multiple signal pathways cancers, such as JAK-STAT, TNF, NF-κB, HIF-1 PI3K-Akt pathways. In addition, knockdown inhibited ability invasion. Immune infiltration indicated immune infiltration. Notably, demonstrated for (AUC = 0.818, P especially stage III-IV patients could reach 0.895. an oncogenic promotes cancer progression related infiltrates, which might be prognostic marker

Language: Английский

---